ANTIDEPRESSANTS IN ANXIETY DISORDERS--DISCONTINUATION/MAINTENANCE W/ IMIPRAMINE

研究的主要目的是：（a）评估 在停用丙咪嗪后恶化/复发，并检测 假设药物的维持可以防止这种逆转， 总共有100名惊恐障碍受试者的实验样本， 广场恐怖症患者对6个月的 随机化前至12个月的系统开放治疗 前瞻性安慰剂对照停药/维持治疗期 研究; B）通过延长治疗时间来评估晚期复发/逆转 双盲安慰剂替代的观察期 c）在24个月内复发的对照评估; 停止1年维持治疗后的12个月 治疗d）从初始随机化起随访3至4年 重新接受治疗的研究完成者和复发者以及受试者 从双盲方案的各个阶段退出， 收集系统的纵向和临床相关数据 特别是因为它们与不同长度的 丙咪嗪维持治疗。

The main objectives of the study are a) to assess the extent of worsening/relapse upon discontinuation of imipramine and to test the hypothesis that maintenance on the drug protects from such reversal in a total experimental sample of 100 subjects with Panic Disorder and Agoraphobia who have shown good and stable response to 6 months of systematic open treatment prior to randomization to the 12 month prospective placebo controlled discontinuation/maintenance phase of the study; b) An evaluation of late relapse/reversals achieved by extending the observation period of the double-blind placebo substitution condition to 24 months; c) A controlled assessment of relapse within the 12 month period following discontinuation of 1 year maintenance treatment d) A follow-up for 3 to 4 years from initial randomization of study completers and relapsers who are retreated as well as subjects who drop out from various stages of the double-blind protocol in order to gather systematic longitudinal and clinically relevant data specifically as they relate to relapse after varying lengths of imipramine maintenance treatment.